| Not Yet Recruiting | Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma NCT07501117 | Inge Marie Svane | Phase 1 |
| Recruiting | Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver NCT07364474 | Massachusetts General Hospital | N/A |
| Recruiting | Neoadjuvant Darovasertib in Primary Uveal Melanoma NCT07015190 | IDEAYA Biosciences | Phase 3 |
| Recruiting | Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects NCT07421739 | Aura Biosciences | — |
| Recruiting | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metast NCT04119024 | Anusha Kalbasi | Phase 1 |
| Recruiting | Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma NCT06070012 | Diwakar Davar | Phase 2 |
| Recruiting | Adding IL-2 to Tebentafusp to Eradicate Cancer Progression NCT07063875 | St Vincent's Hospital, Sydney | Phase 1 / Phase 2 |
| Recruiting | Adjuvant Quisinostat in High-Risk Uveal Melanoma NCT06932757 | University of Miami | Phase 2 |
| Active Not Recruiting | A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma NCT06717126 | iOnctura | Phase 2 |
| Recruiting | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known NCT06805825 | Novelty Nobility, Inc. | Phase 1 |
| Recruiting | Adjuvant Tebentafusp in High Risk Ocular Melanoma NCT06246149 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Recruiting | Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma NCT06550674 | Centre Jean Perrin | N/A |
| Recruiting | PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastase NCT06519266 | Vastra Gotaland Region | Phase 3 |
| Not Yet Recruiting | Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases NCT05903937 | Vastra Gotaland Region | Phase 1 |
| Recruiting | A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-0 NCT06007690 | Aura Biosciences | Phase 3 |
| Unknown | Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal NCT06280040 | Medical University of Vienna | — |
| Active Not Recruiting | Psychoeducation for Uveal Melanoma NCT06075589 | Jonsson Comprehensive Cancer Center | N/A |
| Unknown | Uveal Melanoma - Comparative Study NCT06284512 | Medical University of Vienna | — |
| Unknown | Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-me NCT06073548 | Institut Curie | — |
| Active Not Recruiting | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma NCT05907954 | IDEAYA Biosciences | Phase 2 |
| Active Not Recruiting | A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Sol NCT05812027 | TScan Therapeutics, Inc. | — |
| Recruiting | Retrospective Register for Uveal Melanoma NCT05733728 | Medical University of Vienna | — |
| Terminated | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors NCT05576077 | Turnstone Biologics, Corp. | Phase 1 |
| Completed | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma NCT05628883 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or D NCT05607095 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma NCT05524935 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Withdrawn | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 NCT05482074 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Adjuvant Melatonin for Uveal Melanoma NCT05502900 | Gustav Stalhammar | Phase 3 |
| Completed | Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. NCT05542342 | Grupo Español Multidisciplinar de Melanoma | Phase 2 |
| Active Not Recruiting | Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma NCT05496686 | Modulation Therapeutics, Inc. | Phase 1 |
| Completed | Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Mel NCT05004025 | HonorHealth Research Institute | Phase 1 |
| Unknown | A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma NCT05077280 | California Pacific Medical Center Research Institute | Phase 2 |
| Active Not Recruiting | A Prospective Natural History Study in Uveal Melanoma NCT04588662 | Columbia University | — |
| Enrolling By Invitation | Melphalan Chemoreduction for Ocular Melanoma NCT05893654 | Hospital das Clínicas de Ribeirão Preto | Phase 1 / Phase 2 |
| Unknown | The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma NCT05179174 | University of Catania | — |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876 | SOLTI Breast Cancer Research Group | Phase 2 |
| Completed | Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metast NCT04463368 | Vastra Gotaland Region | Phase 1 |
| Terminated | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma NCT04589832 | Arkadiusz Z. Dudek, MD | Phase 1 / Phase 2 |
| Completed | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positiv NCT04551352 | Hoffmann-La Roche | Phase 1 |
| Completed | Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With M NCT04364230 | Craig L Slingluff, Jr | Phase 1 / Phase 2 |
| Completed | Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With P NCT04417530 | Aura Biosciences | Phase 2 |
| Completed | Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients (EarlyTogether) NCT04728113 | Institut Curie | N/A |
| Recruiting | Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) NCT04424719 | Institut Curie | N/A |
| Active Not Recruiting | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With M NCT04645680 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma NCT04184518 | Grupo Español Multidisciplinar de Melanoma | Phase 2 |
| Active Not Recruiting | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers NCT04328844 | iOnctura | Phase 1 |
| Withdrawn | Vorinostat in Patients With Class 2 High Risk Uveal Melanoma NCT03022565 | University of Miami | EARLY_Phase 1 |
| Terminated | Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma NCT03712904 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Unknown | Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) NCT04025424 | Russian Academy of Medical Sciences | — |
| Active Not Recruiting | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL NCT03635632 | Baylor College of Medicine | Phase 1 |
| Completed | Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma NCT03922880 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients NCT05377957 | Leiden University Medical Center | — |
| Terminated | A Phase 1 Study of [225Ac]-FPI-1434 Injection NCT03746431 | Fusion Pharmaceuticals Inc. | Phase 1 |
| Completed | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies NCT03652077 | Incyte Corporation | Phase 1 |
| Active Not Recruiting | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas NCT03611868 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Completed | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) NCT03207347 | University of Florida | Phase 2 |
| Terminated | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma NCT03417739 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) NCT03408587 | Viralytics | Phase 1 |
| Completed | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma NCT03070392 | Immunocore Ltd | Phase 2 |
| Completed | A Study of PLX2853 in Advanced Malignancies. NCT03297424 | Opna Bio LLC | Phase 1 |
| Terminated | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma NCT02743611 | Bellicum Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Intermittent Selumetinib for Uveal Melanoma NCT02768766 | Shaheer A. Khan | Phase 1 |
| Completed | Study in Subjects With Small Primary Choroidal Melanoma NCT03052127 | Aura Biosciences | Phase 1 / Phase 2 |
| Completed | Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma NCT03964298 | Institut Curie | — |
| Unknown | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases NCT02913417 | David Minor, MD | Phase 1 / Phase 2 |
| Completed | Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma NCT02771340 | Iconic Therapeutics, Inc. | Phase 1 |
| Completed | Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melan NCT02626962 | Grupo Español Multidisciplinar de Melanoma | Phase 2 |
| Completed | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma NCT02570308 | Immunocore Ltd | Phase 1 / Phase 2 |
| Terminated | A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. NCT02601378 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metas NCT02936388 | Charite University, Berlin, Germany | Phase 2 |
| Recruiting | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome NCT04792463 | Mohamed Abdel-Rahman | — |
| Completed | Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy NCT02223819 | Columbia University | Phase 2 |
| Unknown | TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy NCT02379000 | Charite University, Berlin, Germany | Phase 4 |
| Completed | Trial of AEB071 in Combination With BYL719 in Patients With Melanoma NCT02273219 | Columbia University | Phase 1 |
| Completed | Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Cand NCT02849145 | Institut Curie | N/A |
| Completed | Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma NCT01983748 | University Hospital Erlangen | Phase 3 |
| Terminated | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin NCT02029690 | Polaris Group | Phase 1 |
| Completed | Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) NCT01974752 | AstraZeneca | Phase 3 |
| Terminated | Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma NCT01471054 | Arman Mashayekhi | Phase 2 |
| Completed | Vascular Response to Brachytherapy Using Functional OCT NCT01955941 | OHSU Knight Cancer Institute | — |
| Terminated | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma NCT01801358 | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 / Phase 2 |
| Completed | New Biopsy Technique for Uveal Melanoma NCT01924923 | Greater Houston Retina Research | — |
| Completed | Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (En NCT02874040 | Institut Curie | N/A |
| Completed | Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treat NCT01338389 | Centre Hospitalier Universitaire de Nice | N/A |
| Completed | Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal NCT02517736 | University Hospital, Caen | Phase 2 |
| Completed | Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients NCT01430416 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma NCT01438658 | Hadassah Medical Organization | — |
| Unknown | A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma NCT01377025 | Prof. Dr. med. Max. E. Scheulen | Phase 2 |
| Completed | Uveal Melanoma and Brachytheraphy: Long-term Outcomes. NCT04577742 | Federico II University | — |
| Completed | RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma NCT01252251 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outc NCT02376920 | Castle Biosciences Incorporated | — |
| Unknown | Treatment Of Radiation Retinopathy Trial NCT00811200 | Leiden University Medical Center | Phase 2 / Phase 3 |
| Completed | Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma NCT01034787 | AHS Cancer Control Alberta | Phase 2 |
| Completed | Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma NCT02843386 | Institut Curie | Phase 3 |
| Terminated | Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients NCT00929019 | Radboud University Medical Center | Phase 1 / Phase 2 |
| Unknown | Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma NCT00872391 | Medical University of Vienna | N/A |
| Unknown | Morphological, Genetic and Tumour Microenvironment Characterisation in Uveal Melanoma NCT05889481 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Completed | Treatment With Intravitreal Avastin for Large Uveal Melanomas NCT00596362 | Memorial Sloan Kettering Cancer Center | N/A |
| Unknown | Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy NCT00540930 | Shields, Shields and Associates | Phase 4 |
| Completed | Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone NCT00351728 | Jonsson Comprehensive Cancer Center | — |
| Completed | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma NCT00121225 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF NCT00661622 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Unknown | Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma NCT00459849 | Barnes Retina Institute | N/A |
| Available | A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp NCT04960891 | Immunocore Ltd | — |